<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928081</url>
  </required_header>
  <id_info>
    <org_study_id>2015267</org_study_id>
    <nct_id>NCT02928081</nct_id>
  </id_info>
  <brief_title>Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma</brief_title>
  <official_title>Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Liverpool University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the performance of extended lymphadenectomy in
      association with pancreatoduodenectomy improves the long-term survival in patients with
      pancreatic head ductal adenocarcinoma.Half of participants will receive pancreatoduodenectomy
      with extended lymphadenectomy,while the other half will receive pancreatoduodenectomy with
      standard lymphadenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is a common malignant disease of the digestive system, and its incidence
      has been steadily increasing recently. Currently, the only potential curative treatment for
      pancreatic cancer is radical surgery. However, due to the peculiarity of the anatomical
      location of pancreas (in the retroperitoneum, surrounded by peripheral nerves and blood
      vessels) and its biological characteristics (neurotropic, highly malignant, and with probable
      skip metastasis), it is difficult to achieve R0 resection in patients with pancreatic cancer.
      High postoperative recurrence and distant metastasis rate are key factors in reducing
      long-term survival of patients with pancreatic cancer. The radical surgery modalities for
      pancreatoduodenectomy to achieve R0 resection involve extended lymphadenectomy, multivisceral
      resections, with or without simultaneous vein removals. Currently, the lymphadenectomy extent
      and approaches used to achieve R0 status are diverse. In 2014, the International Study Group
      for Pancreatic Surgery (ISGPS) reached a consensus to strive to resect lymph nodes (LNs) 5,
      6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b in standard lymphadenectomy for
      pancreatoduodenectomy. However, no consensus was reached on dissection of LN 16 due to
      variation in the literature and different expert opinions. On the current evidence, benefit
      of extended lymph node dissection seems to be outweighed by the risks. But deficiencies exist
      in the design of previous RCTs, such as insufficient sample size, lack of certain critical
      data for statistical analysis, inclusion of other pathological types of pancreatic neoplasms
      and variable retroperitoneal lymph node resection and nerve plexus dissection . Therefore,
      the power of evidence was low. Most studies report a high frequency of lymph node metastasis
      to LNs 13, 14, 17, 12 and 16 in pancreatic cancer, and tendency to metastasis from LNs 13, 14
      to LN 16. In a lot of case reports, only nodal station 16a2 and 16b1 were positive in LN 16.

      This study is performed to confirm whether pancreatoduodenectomy with extended
      lymphadenectomy could improve survival. Subjects undergoing surgery will be randomized to
      pancreatoduodenectomy with extended lymphadenectomy including nerve tissues around CHA and
      the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) versus standard
      pancreatoduodenectomy. Subjects will be followed every three months for survivorship or
      death. The primary endpoint of 5-year overall or disease-free survival survival will be
      determined at five year post surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year overall survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>The percentage of patients that are alive at a 5 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pancreatic fistula</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>ISGPS definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile leakage</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>ISGLS definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed gastric emptying</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>ISGPS definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-pancreatectomy haemorrhage</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>ISGPS definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-abdominal infection</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>Presence of fever, signs of peritonitis, high leukocytes count or positive peritoneal drainage fluid culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection</measure>
    <time_frame>Within 30 days or before discharge</time_frame>
    <description>Requiring invasive treatment, for example: positive wound exudate culture and requiring continuous re-open drainage or invasive treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>Within 30 days or 60 days</time_frame>
    <description>Death due to any cause before or at postoperative day 30 and 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 or 3 or 5 year</time_frame>
    <description>EORTC QLQ-C30, according to the scoring manual published by the EORTC Quality of Life group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>The percentage of patients alive without recurrence at a 5 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Carcinoma, Pancreatic Ductal</condition>
  <arm_group>
    <arm_group_label>Extended lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard lymphadenectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extended lymphadenectomy</intervention_name>
    <description>Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)</description>
    <arm_group_label>Extended lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard lymphadenectomy</intervention_name>
    <description>Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)</description>
    <arm_group_label>Standard lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was diagnosed with pancreatic ductal adenocarcinoma supported by pathological
             and radiological examination preoperatively

          -  Subject with absence of vascular invasion and metastasis

          -  Subject with absence of prior history of cancer

        Exclusion Criteria:

          -  Subject was diagnosed that other pancreatic tumour types (neuroendocrine tumors,
             intraductal papillary mucinous neoplasm, serous cystadenoma, mucinous
             cystadenocarcinoma, solid pseudopapillary neoplasm and pancreatitis)

          -  Subject was found with liver, omental, mesenteric or peritoneal metastasis
             intraoperatively

          -  Subject with presence of other significant diseases (e.g., coronary heart disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyu Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xubao Liu, MD</last_name>
    <phone>86-28-85422474</phone>
    <email>liuxb2011@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junjie Xiong, MD</last_name>
    <phone>86-28-85422474</phone>
    <email>junjiex2011@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xubao Liu, MD</last_name>
      <phone>86-28-85422474</phone>
      <email>liuxb2011@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Junjie Xiong, MD</last_name>
      <phone>86-28-85422474</phone>
      <email>junjiex2011@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junjie Xiong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongyu Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nengwen Ke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunlu Tan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hao Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bole Tian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weiming Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kezhou Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xiong J, Szatmary P, Huang W, de la Iglesia-Garcia D, Nunes QM, Xia Q, Hu W, Sutton R, Liu X, Raraty MG. Enhanced Recovery After Surgery Program in Patients Undergoing Pancreaticoduodenectomy: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016 May;95(18):e3497. doi: 10.1097/MD.0000000000003497. Review.</citation>
    <PMID>27149448</PMID>
  </reference>
  <reference>
    <citation>Xiong JJ, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, Nunes QM, Sutton R, Liu XB. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Br J Surg. 2014 Sep;101(10):1196-208. doi: 10.1002/bjs.9553. Epub 2014 Jul 16. Review.</citation>
    <PMID>25042895</PMID>
  </reference>
  <results_reference>
    <citation>Chen Y, Ke N, Tan C, Zhang H, Wang X, Mai G, Liu X. Continuous versus interrupted suture techniques of pancreaticojejunostomy after pancreaticoduodenectomy. J Surg Res. 2015 Feb;193(2):590-7. doi: 10.1016/j.jss.2014.07.066. Epub 2014 Aug 5.</citation>
    <PMID>25175768</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Tan C, Mai G, Ke N, Liu X. Resection of pancreatic tumors involving the anterior surface of the superior mesenteric/portal veins axis: an alternative procedure to pancreaticoduodenectomy with vein resection. J Am Coll Surg. 2013 Oct;217(4):e21-8. doi: 10.1016/j.jamcollsurg.2013.07.383.</citation>
    <PMID>24054418</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Wang X, Ke N, Mai G, Liu X. Inferior mesenteric vein serves as an alternative guide for transection of the pancreatic body during pancreaticoduodenectomy with concomitant vascular resection: a comparative study evaluating perioperative outcomes. Eur J Med Res. 2014 Aug 21;19:42. doi: 10.1186/s40001-014-0042-z.</citation>
    <PMID>25141915</PMID>
  </results_reference>
  <results_reference>
    <citation>Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda Y, Sakoda K, Kinoshita T, Yasui K, Shimada H, Katoh H. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012 May;19(3):230-41. doi: 10.1007/s00534-011-0466-6.</citation>
    <PMID>22038501</PMID>
  </results_reference>
  <results_reference>
    <citation>Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Yu HC, Kang KJ, Kim SG, Kim SW. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014 Apr;259(4):656-64. doi: 10.1097/SLA.0000000000000384.</citation>
    <PMID>24368638</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Chen Hongyu</investigator_full_name>
    <investigator_title>Hongyu Chen,MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

